Characteristics of the HSCT cohort according to transplant type
Variable . | Myeloablative . | Nonmyeloablative . |
|---|---|---|
| No. of patients | 197 | 67 |
| Median age, y (range) | 42 (18-62) | 52 (21-66) |
| Male, % | 58.4 | 62.7 |
| HLA matching, %* | ||
| Matched-related | 50.8 | 46.3 |
| Matched-unrelated | 30.9 | 49.2 |
| Mismatched-related | 5.1 | 3.0 |
| Mismatched-unrelated | 13.2 | 1.5 |
| Stem cell source, % | ||
| Bone marrow | 82.2 | 3.0 |
| Peripheral | 17.8 | 97.0 |
| Conditioning regimen, % | ||
| Cyclophosphamide | 100 | 0 |
| TBI | 94.9 | 0 |
| ATG | 1.5 | 0 |
| Busulfan | 3.6 | 100 |
| Fludarabine | 0 | 100 |
| Diagnosis, % | ||
| AML | 31.0 | 28.4 |
| CML | 18.3 | 11.9 |
| MDS | 15.2 | 13.4 |
| NHL | 9.6 | 19.4 |
| ALL | 14.7 | 3.0 |
| CLL | 2.0 | 11.9 |
| Other | 9.1 | 11.9 |
| Risk group, %† | ||
| Low | 36.6 | 11.9 |
| High | 63.4 | 88.1 |
| CMV serology of donor/recipient, %‡ | ||
| D-/R- | 48.2 | 39.7 |
| D-/R+ | 13.7 | 22.4 |
| D+/R- | 19.3 | 25.9 |
| D+/R+ | 18.8 | 12.1 |
| GVHD prophylaxis, %§ | ||
| Methotrexate | 72.1 | 0 |
| Cyclosporine | 27.4 | 100 |
| Tacrolimus | 54.3 | 0 |
| Sirolimus | 21.8 | 0 |
| MMF | 1.0 | 16.4 |
| T-cell manipulation∥ | 22.8 | 6.0 |
| Corticosteroids | 18.8 | 94.0 |
| Total patient-days | 64 759 | 18 485 |
| Median follow-up, d (IQR) | 255 (102-527) | 250 (181-341) |
| Median survival, d (95% CI) | 468 (257-871 +) | 341 (249-503) |
Variable . | Myeloablative . | Nonmyeloablative . |
|---|---|---|
| No. of patients | 197 | 67 |
| Median age, y (range) | 42 (18-62) | 52 (21-66) |
| Male, % | 58.4 | 62.7 |
| HLA matching, %* | ||
| Matched-related | 50.8 | 46.3 |
| Matched-unrelated | 30.9 | 49.2 |
| Mismatched-related | 5.1 | 3.0 |
| Mismatched-unrelated | 13.2 | 1.5 |
| Stem cell source, % | ||
| Bone marrow | 82.2 | 3.0 |
| Peripheral | 17.8 | 97.0 |
| Conditioning regimen, % | ||
| Cyclophosphamide | 100 | 0 |
| TBI | 94.9 | 0 |
| ATG | 1.5 | 0 |
| Busulfan | 3.6 | 100 |
| Fludarabine | 0 | 100 |
| Diagnosis, % | ||
| AML | 31.0 | 28.4 |
| CML | 18.3 | 11.9 |
| MDS | 15.2 | 13.4 |
| NHL | 9.6 | 19.4 |
| ALL | 14.7 | 3.0 |
| CLL | 2.0 | 11.9 |
| Other | 9.1 | 11.9 |
| Risk group, %† | ||
| Low | 36.6 | 11.9 |
| High | 63.4 | 88.1 |
| CMV serology of donor/recipient, %‡ | ||
| D-/R- | 48.2 | 39.7 |
| D-/R+ | 13.7 | 22.4 |
| D+/R- | 19.3 | 25.9 |
| D+/R+ | 18.8 | 12.1 |
| GVHD prophylaxis, %§ | ||
| Methotrexate | 72.1 | 0 |
| Cyclosporine | 27.4 | 100 |
| Tacrolimus | 54.3 | 0 |
| Sirolimus | 21.8 | 0 |
| MMF | 1.0 | 16.4 |
| T-cell manipulation∥ | 22.8 | 6.0 |
| Corticosteroids | 18.8 | 94.0 |
| Total patient-days | 64 759 | 18 485 |
| Median follow-up, d (IQR) | 255 (102-527) | 250 (181-341) |
| Median survival, d (95% CI) | 468 (257-871 +) | 341 (249-503) |
Follow-up ended on June 30, 2002, for analysis. The table includes the patients who received an HSC transplant from January 1, 2000, to December 31, 2001, except those excluded as explained in the text. TBI indicates total body irradiation; ATG, antithymocyte globulin; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; ALL, acute lymphocytic leukemia; CLL, chronic lymphocytic leukemia; and other, other hematologic malignancies (myeloproliferative syndromes, Hodgkin disease, multiple myeloma, etc).
Patients were considered HLA matched if all 6 of 6 HLA-A, -B and -DR were identical.
Diseases considered low risk were AML or ALL in first complete remission, CML in first chronic phase, aplastic anemia, refractory anemia, and refractory anemia with ringed sideroblasts; all other diseases were considered high risk.
CMV serology data were incomplete in 9 nonmyeloablative recipients (n = 58).
Most patients received more than one intervention for GVHD prophylaxis except for the subgroup that received a CD6 T-cell—depleted transplant, which received no other prophylaxis.
T-cell manipulations included CD6 depletion, CD8 depletion, or CD34 selection, depending on the treatment protocol used.